Cargando…
The type I interferon response in COVID-19: implications for treatment
Despite early reports to the contrary, there is increasing evidence that patients with severe COVID-19 have a robust type I interferon response, which contrasts with the delayed, possibly suppressed, interferon response seen early in infection. A robust type I interferon response could exacerbate hy...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824445/ https://www.ncbi.nlm.nih.gov/pubmed/32788708 http://dx.doi.org/10.1038/s41577-020-00429-3 |
_version_ | 1784647018965106688 |
---|---|
author | Lee, Jeong Seok Shin, Eui-Cheol |
author_facet | Lee, Jeong Seok Shin, Eui-Cheol |
author_sort | Lee, Jeong Seok |
collection | PubMed |
description | Despite early reports to the contrary, there is increasing evidence that patients with severe COVID-19 have a robust type I interferon response, which contrasts with the delayed, possibly suppressed, interferon response seen early in infection. A robust type I interferon response could exacerbate hyperinflammation in the progression to severe COVID-19 through diverse mechanisms. Further understanding of the roles of type I interferon at different stages of infection and in patients with mild versus severe COVID-19 will provide insights for the therapeutic use of interferon administration or JAK inhibitors in patients with COVID-19. |
format | Online Article Text |
id | pubmed-8824445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-88244452022-02-18 The type I interferon response in COVID-19: implications for treatment Lee, Jeong Seok Shin, Eui-Cheol Nat Rev Immunol Comment Despite early reports to the contrary, there is increasing evidence that patients with severe COVID-19 have a robust type I interferon response, which contrasts with the delayed, possibly suppressed, interferon response seen early in infection. A robust type I interferon response could exacerbate hyperinflammation in the progression to severe COVID-19 through diverse mechanisms. Further understanding of the roles of type I interferon at different stages of infection and in patients with mild versus severe COVID-19 will provide insights for the therapeutic use of interferon administration or JAK inhibitors in patients with COVID-19. Nature Publishing Group UK 2020-08-12 2020 /pmc/articles/PMC8824445/ /pubmed/32788708 http://dx.doi.org/10.1038/s41577-020-00429-3 Text en © Springer Nature Limited 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Comment Lee, Jeong Seok Shin, Eui-Cheol The type I interferon response in COVID-19: implications for treatment |
title | The type I interferon response in COVID-19: implications for treatment |
title_full | The type I interferon response in COVID-19: implications for treatment |
title_fullStr | The type I interferon response in COVID-19: implications for treatment |
title_full_unstemmed | The type I interferon response in COVID-19: implications for treatment |
title_short | The type I interferon response in COVID-19: implications for treatment |
title_sort | type i interferon response in covid-19: implications for treatment |
topic | Comment |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824445/ https://www.ncbi.nlm.nih.gov/pubmed/32788708 http://dx.doi.org/10.1038/s41577-020-00429-3 |
work_keys_str_mv | AT leejeongseok thetypeiinterferonresponseincovid19implicationsfortreatment AT shineuicheol thetypeiinterferonresponseincovid19implicationsfortreatment AT leejeongseok typeiinterferonresponseincovid19implicationsfortreatment AT shineuicheol typeiinterferonresponseincovid19implicationsfortreatment |